指南与共识胸部肿瘤

亚洲胸部肿瘤研究组III期非小细胞肺癌最佳管理专家共识

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC.
指南 / 共识 · J Thorac Oncol · 2019-11-13

亚洲胸部肿瘤研究组召集来自香港、韩国、日本、台湾、新加坡、泰国、马来西亚和中国大陆的多学科专家,针对III期非小细胞肺癌(NSCLC)从初始诊断分期到手术、化疗、放疗、靶向治疗和免疫治疗等多模式管理,讨论亚洲各国标准临床实践并形成专家共识。

要点

  • AJCC第八版分期重新定义了III期NSCLC的TNM亚组(IIIA-C),以改善预后判断。
  • 亚洲NSCLC在吸烟率、驱动基因突变流行率及医疗资源可及性方面存在差异,应用临床试验数据需谨慎。

核心结论

  • III期NSCLC异质性强,最佳治疗仍具临床挑战,需多学科协作并考虑亚洲人群特征。

研究设计与样本

  • 亚洲胸部肿瘤研究组召集来自香港、韩国、日本、台湾、新加坡、泰国、马来西亚和中国大陆的多学科专家形成专家共识。

主要发现

  • AJCC第八版分期改变了III期NSCLC的TNM分组并重新定义了IIIA-C亚组以改善预后判断。
  • 当代考量包括NSCLC不同分子亚型的影响、根治性治疗后TKI的作用以及放化疗后免疫检查点抑制剂的作用。
  • 亚洲NSCLC在吸烟率、致癌驱动基因突变流行率和包括分子检测在内的医疗资源可及性方面存在差异。

临床怎么用

  • III期NSCLC管理需要肿瘤内科、放疗科、呼吸科、影像科、病理科和胸外科等多学科参与。
  • 亚洲临床应用试验数据时需考虑吸烟率、驱动基因突变流行率及分子检测等资源可及性的地区差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA-C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades, contemporary considerations include the impact of different molecular subsets of NSCLC, and the roles of tyrosine kinase inhibitors post-definitive therapy and of immune checkpoint inhibitors following chemoradiotherapy. With rapid evolution of diagnostic algorithms and expanding treatment options, the need for interdisciplinary input involving multiple specialists (medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and thoracic surgeons) has become increasingly important. The unique demographics of Asian NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources including molecular testing, prompting the need for critical review of existing data and identification of current gaps. In this expert consensus statement by the Asian Thoracic Oncology Research Group, an interdisciplinary group of experts representing Hong Kong, Korea, Japan, Taiwan, Singapore, Thailand, Malaysia, and Mainland China was convened. Standard clinical practices for stage III NSCLC across different Asian countries were discussed from initial diagnosis and staging through to multi-modality approaches including surgery, chemotherapy, radiation, targeted therapies, and immunotherapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Tan WL, Chua KLM, Lin CC, et al. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. J Thorac Oncol. 2019. PMID: 31733357. doi:10.1016/j.jtho.2019.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。